Shots:
- Vir Biotechnology has enrolled the first pts in P-III (ECLIPSE 2) trial assessing tobevibart + elebsiran in CHD pts who have not achieved undetectable HDV RNA despite prior bulevirtide treatment
- Trial will assess CHD pts treated with bulevirtide for ≥24wks., randomized to either switch to tobevibart + elebsiran or continue bulevirtide, with the 1EP of HDV RNA TND (0 IU/mL) at Wk. 24; trial data to support regulatory filings, along with ECLIPSE 1 results
- Tobevibart + elebsiran is being assessed in ECLIPSE Program, which incl. P-III (ECLIPSE 1) trial against deferred treatment in regions with limited bulevirtide access & P-IIb (ECLIPSE 3) trial against bulevirtide in bulevirtide-naïve pts
Ref: Vir Biotechnology| Image: Vir Biotechnology | Press Release
Related News:- Eli Lilly Reports Topline P-III (BRUIN CLL-314) Trial Results of Jaypirca (Pirtobrutinib) to Treat CLL/SLL
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
